EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Model-Informed Dose Optimization of Pazopanib in Real-World Patients with Cancer

Zhiyuan Tan, Swantje Völler, Anyue Yin, Amy Rieborn, Hans Gelderblom, Tom van der Hulle, Catherijne A J Knibbe, Dirk Jan A R Moes iD

Clinical Pharmacokinetics · 2025

DOI: 10.1007/s40262-025-01504-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacokinetics, 2025. Verfasst von Zhiyuan Tan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Systems Pharmacology and Pharmacy, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Sulfonamides, Pyrimidines, Models, Biological, Angiogenesis Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVES: Pazopanib is approved for metastatic renal cell carcinoma (mRCC) and soft tissue sarcoma (STS) in a dose of 800 mg once daily (QD) taken under fasted conditions. In clinical practice, approximately 60% of patients require dose reductions due to toxicity, with severe liver toxicity necessitating treatment interruptions in over 10% of cases. While a trough concentration (Cmin,ss) target of ≥ 20.5 mg/L has been established for mRCC efficacy, no specific threshold exists for liver toxicity. The objectives of this study were to develop a population pharmacokinetic (POPPK), an exposure-liver toxicity, and an exposure-tumor size dynamics model to optimize pazopanib initial dose in real-world patients. METHODS: In total, 135 patients were included and treated with a median starting dose of 800 mg (interquartile range, IQR: 600-800 mg) QD pazopanib fasted with a median follow-up of 120 (IQR 63-372) days. A population pharmacokinetic model was developed using 460 concentration measurements from 135 patients. Exposure-liver toxicity was evaluated using time-to-event modeling, and exposure-tumor size dynamics was evaluated using tumor growth modelling. RESULTS: The liver toxicity model, with 27 cases of grade ≥ 2 liver toxicity out of 135 patients (20%), identified a Cmin,ss threshold of > 34 mg/L associated with a 3.35-fold increased toxicity risk (P < 0.01). Model simulations showed that an initial dose of 600 mg QD significantly reduced liver toxicity risk (P < 0.001) while maintaining Cmin,ss ≥ 20.5 mg/L for 76% of the simulated individuals. Tumor size dynamics were analyzed using baseline and posttreatment tumor size measurements from 111 patients. The introduction of primary resistance by using a mixture model improved the model fit significantly. Tumor growth and decay rates differed between mRCC and STS but showed no pazopanib exposure dependency across the studied range, suggesting maximal tumor inhibition at current exposure levels. CONCLUSIONS: These findings suggest that an initial pazopanib dose of 600 mg fasted, followed by model-informed precision dosing to maintain Cmin,ss between 20 and 34 mg/L, may improve efficacy-toxicity balance and mitigate treatment interruptions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SulfonamidesPyrimidinesModels, BiologicalAngiogenesis InhibitorsHumansIndazolesFemaleMaleMiddle AgedAgedDose-Response Relationship, DrugCarcinoma, Renal CellKidney NeoplasmsSarcomaAdultChemical and Drug Induced Liver InjuryAged, 80 and over

Substanzen

pazopanibIndazolesSulfonamidesPyrimidinesAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Division of Systems Pharmacology and Pharmacy, Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands.
  • Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
  • Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Clinical Pharmacy, St Antonius Hospital, Nieuwegein, The Netherlands.
  • Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. d.j.a.r.moes@lumc.nl.

ORCID-Profile: Dirk Jan A R Moes

Zitieren

APA

Tan, Z., Völler, S., Yin, A., Rieborn, A., Gelderblom, H., van der Hulle, T., Knibbe, C. A. J., & Moes, D. J. A. R. (2025). Model-Informed Dose Optimization of Pazopanib in Real-World Patients with Cancer. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-025-01504-5

Vancouver

Tan Z, Völler S, Yin A, Rieborn A, Gelderblom H, van der Hulle T, et al. Model-Informed Dose Optimization of Pazopanib in Real-World Patients with Cancer. Clinical Pharmacokinetics. 2025. doi:10.1007/s40262-025-01504-5

BibTeX
@article{Tan2025,
  author = {Tan, Zhiyuan and Völler, Swantje and Yin, Anyue and Rieborn, Amy and Gelderblom, Hans and van der Hulle, Tom and Knibbe, Catherijne A J and Moes, Dirk Jan A R},
  title = {Model-Informed Dose Optimization of Pazopanib in Real-World Patients with Cancer},
  journal = {Clinical Pharmacokinetics},
  year = {2025},
  doi = {10.1007/s40262-025-01504-5}
}
Kostenlos starten →